Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
FGFR3 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FGFR3 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FGFR2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FGFR2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FGFR1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FGFR1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
NTRK3 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
NTRK3 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
NTRK2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
NTRK2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
NTRK1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
NTRK1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
RET 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
RET 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
ROS1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
ROS1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
ALK 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
ALK 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
MET 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
MET 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
ERBB4 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
ERBB4 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
ERBB3 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
ERBB3 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.